Media Summary: Neal Shore, MD, Carolina Urologic Research Center, and Sia Daneshmand, MD, University of Southern California, discuss a ... Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, South Carolina, reviews whether ... Join us in this insightful episode as we delve into the latest advancements in the management of non-muscle-invasive bladder ...

Crest Sasanlimab Plus Bcg For High Risk Nmibc - Detailed Analysis & Overview

Neal Shore, MD, Carolina Urologic Research Center, and Sia Daneshmand, MD, University of Southern California, discuss a ... Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, South Carolina, reviews whether ... Join us in this insightful episode as we delve into the latest advancements in the management of non-muscle-invasive bladder ... Dr. Gary Steinberg MD discusses the management of Dr Bedke discusses quality of life data from the findings from the Gordon Brown, DO, Summit Health, breaks down the

Jennifer M. Taylor, MD, MPH, Assistant Professor of Urology Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, shares how In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive ... Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, talks about this new adenovirus ... Trinity J. Bivalacqua, MD, PhD, Director of Urologic Oncology

In this webinar, urologist Katie Murray, DO, of NYU Langone Cancer Center explains how Felix Guerrero-Ramos, MD, PhD, from Hospital Universitario 12 de Octubre in Madrid, Spain, provides insights into non-muscle ... 2021 KPS-APSU Joint International Symposium Session II: Urothelial Cancer I What is the Optimal Therapy for

Photo Gallery

CREST: Sasanlimab Plus BCG for High-Risk NMIBC
Sasanlimab BCG combo improves outcomes in high-risk NMIBC
Treatment of High-Risk NMIBC: Is BCG Still the Best Option?
Immunotherapy Plus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer
Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series
QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC
CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown on IO-BCG Combinations
Immunotherapy for NMIBC: Emerging and Expanding Indications
How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?
Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks
BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC
Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC
Sponsored
Sponsored
View Detailed Profile
CREST: Sasanlimab Plus BCG for High-Risk NMIBC

CREST: Sasanlimab Plus BCG for High-Risk NMIBC

Neal Shore, MD, Carolina Urologic Research Center, and Sia Daneshmand, MD, University of Southern California, discuss a ...

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Dr Powles talks to ecancer

Sponsored
Treatment of High-Risk NMIBC: Is BCG Still the Best Option?

Treatment of High-Risk NMIBC: Is BCG Still the Best Option?

Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, South Carolina, reviews whether ...

Immunotherapy Plus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

Immunotherapy Plus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

Join us in this insightful episode as we delve into the latest advancements in the management of non-muscle-invasive bladder ...

Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series

Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series

Dr. Gary Steinberg MD discusses the management of

Sponsored
QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Dr Bedke discusses quality of life data from the findings from the

CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown on IO-BCG Combinations

CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown on IO-BCG Combinations

Gordon Brown, DO, Summit Health, breaks down the

Immunotherapy for NMIBC: Emerging and Expanding Indications

Immunotherapy for NMIBC: Emerging and Expanding Indications

Jennifer M. Taylor, MD, MPH, Assistant Professor of Urology

How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?

How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, shares how

Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks

Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive ...

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Dr Hayne talks to ecancer

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec

High Grade Bladder Cancer: BCG Assessment, Treatment & Maintenance

High Grade Bladder Cancer: BCG Assessment, Treatment & Maintenance

Dr. Tom Jayaram shares his approach to

Introduction to Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC

Introduction to Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC

Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, talks about this new adenovirus ...

UROWebinar: NMIBC – BCG Unresponsive management in 2025 and new developments

UROWebinar: NMIBC – BCG Unresponsive management in 2025 and new developments

NMIBC

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

Trinity J. Bivalacqua, MD, PhD, Director of Urologic Oncology

Managing NMIBC in the BCG Shortage Era

Managing NMIBC in the BCG Shortage Era

Seth P. Lerner, MD, explains the

Webinar: Treating Non-Muscle Invasive Bladder Cancer by Risk Level Part 2 of 4.

Webinar: Treating Non-Muscle Invasive Bladder Cancer by Risk Level Part 2 of 4.

In this webinar, urologist Katie Murray, DO, of NYU Langone Cancer Center explains how

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies

Felix Guerrero-Ramos, MD, PhD, from Hospital Universitario 12 de Octubre in Madrid, Spain, provides insights into non-muscle ...

What is the Optimal Therapy for BCG Unresponsive High-Risk NMIBC:

What is the Optimal Therapy for BCG Unresponsive High-Risk NMIBC:

2021 KPS-APSU Joint International Symposium Session II: Urothelial Cancer I What is the Optimal Therapy for